MacroGenics (MGNX) & Viking Therapeutics (VKTX) Head-To-Head Contrast
MacroGenics (NASDAQ: MGNX) and Viking Therapeutics (NASDAQ:VKTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.
Institutional & Insider Ownership
85.8% of MacroGenics shares are owned by institutional investors. Comparatively, 7.5% of Viking Therapeutics shares are owned by institutional investors. 8.3% of MacroGenics shares are owned by insiders. Comparatively, 8.2% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares MacroGenics and Viking Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|MacroGenics||$91.88 million||7.84||-$58.52 million||($4.50)||-4.35|
|Viking Therapeutics||N/A||N/A||-$14.73 million||($0.84)||-3.26|
Viking Therapeutics has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and recommmendations for MacroGenics and Viking Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
MacroGenics currently has a consensus price target of $31.33, suggesting a potential upside of 60.11%. Viking Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 155.47%. Given Viking Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than MacroGenics.
This table compares MacroGenics and Viking Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
MacroGenics has a beta of 2.73, suggesting that its share price is 173% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500.
MacroGenics beats Viking Therapeutics on 7 of the 12 factors compared between the two stocks.
MacroGenics Company Profile
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company’s product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.
Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.